Tozasertib has entered phase I/II clinical trials for the treatment of solid tumours44, chronic myeloid leukaemia and acute lymphocytic leukaemia with T351I BCR-ABL mutations45–47. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.